Skip to content

Collection of Human Metabolic Tissues

Study of New Determinants of Type 2 Diabetes in Severe Obesity

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02861781
Acronym
COMET
Enrollment
270
Registered
2016-08-10
Start date
2016-02-02
Completion date
2028-09-01
Last updated
2026-05-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes Mellitus, Type 2, Insulin Resistance, Obesity

Keywords

Bariatric surgery

Brief summary

This project aims at identifying new determinants of type 2 diabetes in severe obesity. To do so, a biological collection, including tissues of interest in the field of metabolism, will be collected during bariatric surgery in obese patients. Three different groups of metabolic status of patients, corresponding to different stages of evolution of the disease, will be constituted: type 2 diabetes, insulin resistance, insulin sensitivity. The main objective is to compare, between these 3 groups of patients, several biological processes that may be involved in the pathophysiology of type 2 diabetes and disorders associated with obesity, including: * Abnormalities of the transcriptome, proteome, metabolome in all target tissues (plasma, serum, muscle, subcutaneous and visceral adipose tissue, omental artery, liver) * Identification of metabolic signatures, protein and miRNA in plasma * Immunoinflammatory response in adipose tissue * Polymorphisms SNP from whole blood * Histological analysis of tissue sections This main objective will be studied on samples taken at the time of surgery Secondary objectives will be to study the changes in metabolites, proteins and miRNA in plasma level 3 and 12 months after the completion of surgery, according to the initial metabolic state.

Interventions

OTHERCollection of blood samples and tissues

Collection of blood samples and tissues during bariatric surgery and blood samples during followup visits

Sponsors

University Hospital, Montpellier
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

1. Written informed consent 2. Age 18 - 65 years inclusive at surgery 3. IMC \> 35 4. Subject qualified for bariatric surgery (sleeve gastrectomy or gastric bypass) 5. Specific criteria : * Type 2 diabetes group (D) (90 patients) : type 2 diabetes according to ADA criteria * Insulin resistance non diabetes group (IR) (80 patients) : HOMA-IR criteria ≥ 3 * Insulin Sensitivity non diabetes group (N) (100 patients) : N1.HOMA-IR criteria \< 3 Non inclusion Criteria: 1. Vulnerability according to article L1121-6 of the Public Health Code 2. Protected adult or unability to give consent according to article L1121-8 of the Public Health Code 3. Unability to understand the design and aims of the study or to communicate with the investigator 4. Non affiliation to a social security system 5. Prior bariatric surgery (except lap-band procedure) 6. Serologic profile indicating hepatitis B, hepatitis C or HIV infection 7. Inflammatory, infectious or autoimmune disease (current or in the previous 3 month) 8. Malignancies within 5 years prior to inclusion or not considered as treated curatively 9. Concomitant use of steroids or NSAI or use in the 8 days before surgery 10. alcohol abuse/addiction 11. Anticipated poor compliance to study procedures 12. Other type of diabetes than type 2

Exclusion criteria

: 1. Cancelled bariatric surgery 2. Tissue collection not possible during the bariatric surgery

Design outcomes

Primary

MeasureTime frameDescription
comparison of metabolitesAt baseline (day of surgery)
comparison of proteins levelsAt baseline (day of surgery)in liver, muscle, adipose tissue and plasma according to metabolic state
comparison of miRNAAt baseline (day of surgery)in liver, muscle, adipose tissue and plasma according to metabolic state

Secondary

MeasureTime frame
changes in metabolites in plasma level3 and 12 months after the completion of surgery
changes in proteins in plasma level3 and 12 months after the completion of surgery
changes in miRNA in plasma level3 and 12 months after the completion of surgery

Countries

France

Contacts

CONTACTFlorence Galtier, MD
f-galtier@chu-montpellier.fr
PRINCIPAL_INVESTIGATORFlorence GALTIER

Montpellier University Hospital

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: May 9, 2026